Ep30: Barbara Weber

Episode Summary

Executive Summary: Barbara Weber traces her path from genetics and oncology in academia to big pharma and finally Tango Therapeutics, where she applies CRISPR-enabled synthetic lethality to find cancer drug targets. The episode explains why context-specific tumor genetics matter, how precision medicine can accelerate development, and why Tango’s Gilead partnership validates the platform and startup model.

Main Topics: Barbara Weber’s career arc: Weber describes moving from academic genetics/oncology (UW, Yale, Dana-Farber, Michigan, Penn) into pharma leadership at GSK and Novartis, then into Third Rock and Tango. Each step shaped her focus on translating genetics into drugs. Synthetic lethality as a cancer strategy: The conversation explains synthetic lethality as targeting two vulnerabilities at once, especially useful for tumor suppressor losses that cannot be directly drugged. Weber frames it as the core scientific basis for Tango. CRISPR enabling modern target discovery: Weber argues CRISPR transformed what had been technically impractical in 2005 into a scalable discovery platform, allowing genome-scale identification of synthetic lethal pairs in defined cancer contexts. Context dependence in oncology: A central theme is that target efficacy depends on tissue lineage and mutation context; a synthetic lethal pair in one cancer type may not work in another, even with the same gene lesion. From academic science to drug development: Weber contrasts publishing and risk-discovery in academia with the translational and patient-centered focus of pharma and biotech, emphasizing the importance of patient selection from the first dose in trials. Tango’s pipeline and partnership strategy: The company’s early-stage platform is still preclinical, but it has secured a major Gilead deal and is advancing multiple small-molecule programs toward IND filings and eventual clinical testing. Biotech startup building and culture: Weber discusses the challenge of scaling from scratch, the importance of recruiting talent, and Tango’s team-oriented culture reflected in its branding, office move, and sneaker contest.

Key Arguments: Synthetic lethality is especially valuable for tumor suppressor genes because those genes are lost or inactivated, making them difficult to target directly. CRISPR made synthetic lethal screening practical by reducing false positives and enabling scalable, genome-wide target discovery. Cancer targets must be studied in context; the same mutation can yield different therapeutic vulnerabilities depending on tissue of origin and broader mutation spectrum. Selecting patients genetically from the first patient dosed can dramatically shorten drug-development timelines and improve probability of proof of concept. Combination therapy is likely necessary for solid tumors because cancer is too biologically plastic for a single-agent cure in most cases. Tango’s platform can discover targets in specific genetic subtypes, opening opportunities beyond BRCA1/2 and beyond very small patient populations. Partnerships like Gilead’s show that large pharma values external platforms that can replenish pipelines without acquiring full programs early.

Data Points: Gilead upfront payment: $50 million - Gilead paid this amount for an option to license five targets from Tango’s discovery platform. Number of targets in Gilead option: 5 - Tango announced a partnership granting Gilead an option on five newly discovered targets. Company founding year: 2014 - Tango Therapeutics was founded in 2014 and remained preclinical at the time of the interview. Time to clinical proof of concept reduction: 4.5 years to 7 months - Weber says her Novartis precision-medicine strategy reduced median time from first patient dosed to clinical POC. Novartis employment period: 2009-2015 - Weber served at Novartis during the period when the company changed trial design around genetic patient selection. Example response timing: First response in the second patient - She cites seritinib/ceritinib in ALK-translocated cancer as an example of selecting patients from the first dose. Clinical registration timing: Within 3 years - Ceritinib was registered within three years of the first patient dose. Druggable genome library size: ~5,000 genes - Tango uses a CRISPR library covering about 5,000 druggable genes for screening. Gastric cancer ARID-1A subset: 30% to 40% - Weber estimates ARID-1A loss occurs in roughly 30% to 40% of gastric cancers. Tango office move: 100 Binney - Company photos on the website were taken when the team moved from Hurley Street to 100 Binney. Life Science Cares network: 150+ companies - The sponsor mention notes Life Science Cares works with more than 150 companies. Timmerman Report subscription: $149/year - Promotional mention during the podcast introduction.

Pivotal Quotes: "it takes two to tango" — Luke Timmerman: Opening setup for the company’s name and synthetic lethality concept. "We can dramatically change how cancer targeted drug development was being done by selecting patients correctly from the very beginning of phase one." — Barbara Weber: Explaining why her move from academia to pharma mattered for precision oncology. "Every cancer that is cured, that is curable in humans, and there are a number of them, are all cured by combination therapy." — Barbara Weber: Her argument that solid tumors will likely require multi-drug approaches rather than single agents.

Implications: The episode underscores that precision oncology is shifting from broad, one-size-fits-all development toward context-specific, genetically guided combinations. For biotech, CRISPR-based discovery plus disciplined patient selection may produce faster, more capital-efficient drug pipelines.